Literature DB >> 30123328

Nebulization of Single-Chain Tissue-Type and Single-Chain Urokinase Plasminogen Activator for Treatment of Inhalational Smoke-Induced Acute Lung Injury.

Soraya Hengsawas Surasarang1, Sawittree Sahakijpijarn1, Galina Florova2, Andrey A Komissarov2, Christina L Nelson3, Enkhbaatar Perenlei3, Satoshi Fukuda3, Marla R Wolfson4, Thomas H Shaffer4,5, Steven Idell2, Robert O Williams1.   

Abstract

Single-chain tissue-type plasminogen activator (sctPA) and single-chain urokinase plasminogen activator (scuPA) have attracted interest as enzymes for the treatment of inhalational smoke-induced acute lung injury (ISALI). In this study, the pulmonary delivery of commercial human sctPA and lyophilized scuPA and their reconstituted solution forms were demonstrated using vibrating mesh nebulizers (Aeroneb® Pro (active) and EZ Breathe® (passive)). Both the Aeroneb® Pro and EZ Breathe® vibrating mesh nebulizers produced atomized droplets of protein solution of similar size of less than about 5 μm, which is appropriate for pulmonary delivery. Enzymatic activities of scuPA and of sctPA were determined after nebulization and both remained stable (88.0% and 93.9%). Additionally, the enzymatic activities of sctPA and tcuPA were not significantly affected by excipients, lyophilization or reconstitution conditions. The results of these studies support further development of inhaled formulations of fibrinolysins for delivery to the lungs following smoke-induced acute pulmonary injury.

Entities:  

Keywords:  Single-chain tissue-type plasminogen activator; inhalational smoke-induced acute lung injury; lyophilization; nebulization; pulmonary delivery; single-chain urokinase plasminogen activator; vibrating mesh nebulizers

Year:  2018        PMID: 30123328      PMCID: PMC6095669          DOI: 10.1016/j.jddst.2018.04.013

Source DB:  PubMed          Journal:  J Drug Deliv Sci Technol        ISSN: 1773-2247            Impact factor:   3.981


  72 in total

1.  Comparison of nebulized particle size distribution with Malvern laser diffraction analyzer versus Andersen cascade impactor and low-flow Marple personal cascade impactor.

Authors:  W T Kwong; S L Ho; A L Coates
Journal:  J Aerosol Med       Date:  2000

2.  Effect of sorbitol and residual moisture on the stability of lyophilized antibodies: Implications for the mechanism of protein stabilization in the solid state.

Authors:  Liuquan Lucy Chang; Deanna Shepherd; Joanna Sun; Xiaolin Charlie Tang; Michael J Pikal
Journal:  J Pharm Sci       Date:  2005-07       Impact factor: 3.534

Review 3.  Laser diffractometry as a technique for the rapid assessment of aerosol particle size from inhalers.

Authors:  Jolyon P Mitchell; Mark W Nagel; Steve Nichols; Ola Nerbrink
Journal:  J Aerosol Med       Date:  2006

4.  The influence of fluid physicochemical properties on vibrating-mesh nebulization.

Authors:  Thu Ghazanfari; Abdelbary M A Elhissi; Zhiyi Ding; Kevin M G Taylor
Journal:  Int J Pharm       Date:  2007-03-06       Impact factor: 5.875

5.  Advanced nebulizer designs employing vibrating mesh/aperture plate technologies for aerosol generation.

Authors:  J C Waldrep; R Dhand
Journal:  Curr Drug Deliv       Date:  2008-04       Impact factor: 2.565

Review 6.  Aerosol delivery of antimicrobial agents during mechanical ventilation: current practice and perspectives.

Authors:  Argyris Michalopoulos; Eugenios I Metaxas; Matthew E Falagas
Journal:  Curr Drug Deliv       Date:  2011-03       Impact factor: 2.565

7.  Activated protein C attenuates pulmonary coagulopathy in patients with acute respiratory distress syndrome.

Authors:  A D Cornet; J J Hofstra; A P Vlaar; P R Tuinman; M Levi; A R Girbes; M J Schultz; A B Groeneveld; A Beishuizen
Journal:  J Thromb Haemost       Date:  2013-05       Impact factor: 5.824

8.  Prediction of protein degradation during vibrating mesh nebulization via a high throughput screening method.

Authors:  Sebastian Hertel; Thomas Pohl; Wolfgang Friess; Gerhard Winter
Journal:  Eur J Pharm Biopharm       Date:  2014-04-04       Impact factor: 5.571

9.  Some factors associated with the ultrasonic nebulization of proteins.

Authors:  R W Niven; A Y Ip; S Mittelman; S J Prestrelski; T Arakawa
Journal:  Pharm Res       Date:  1995-01       Impact factor: 4.200

10.  The effect of formulation variables on the stability of nebulized aviscumine.

Authors:  Hartwig Steckel; Fadi Eskandar; Klaus Witthohn
Journal:  Int J Pharm       Date:  2003-05-12       Impact factor: 5.875

View more
  1 in total

1.  Perfluorochemical-facilitated plasminogen activator delivery to the airways: A novel treatment for inhalational smoke-induced acute lung injury.

Authors:  Marla R Wolfson; Perenlei Enkhbaatar; Satoshi Fukuda; Christina L Nelson; Robert O Williams; Soraya Hengsawas Surasarang; Sawittree Sahakijpijarn; Gennaro Calendo; Andrey A Komissarov; Galina Florova; Krishna Sarva; Steven I Idell; Thomas H Shaffer
Journal:  Clin Transl Med       Date:  2020-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.